Healthcare & Life Sciences

Covered Stent with Elastic Supporting Member and Imaging Member

The USPTO granted Patent US12599472B2 to Lifetech Scientific (CO.), LTD. for a covered stent invention. The device comprises a hollow tubular main body with a window on its side wall, an elastic supporting member at the window periphery, and an imaging member movably connected to the supporting member. The patent contains 9 claims.

Vascular Device Marker Attachment

USPTO granted Patent US12599458B2 to Covidien LP on April 14, 2026. The patent covers a thrombectomy device with an arcuate marker-mounting projection where the marker contacts the projection at three discrete locations. The device is designed to expand from a first configuration to a second configuration for engaging blood clots in vessels.

LAG-3 Antibody Combination Therapies - Patent US12600777B2

The USPTO granted patent US12600777B2 to Novartis AG covering combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent contains seven claims and relates to methods for treating, preventing, and/or diagnosing cancerous or infectious disorders. This represents a grant of exclusive intellectual property rights to Novartis AG for the therapeutic application of LAG-3 antibody combinations.

Method of Screening Compounds Inhibiting Pancreatic Cancer RNF43 Mutation

The USPTO granted Patent US12600785B2 to Antlera Therapeutics Inc. covering a method of screening compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene. The patent discloses FZD5-binding agents for treating diseases associated with aberrant Frizzled protein expression. The patent contains 5 claims and names Guohua Pan, Jason Moffat, Sachdev Sidhu, Stephane Angers, Zachary Steinhart, and Xiaowei Wang as inventors.

RAGE Antibodies Patent Granted SUNY Apr 14

USPTO granted Patent US12600778B2 to The Research Foundation for The State University of New York for antibodies specific to the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). The patent includes methods for treating conditions involving RAGE through antibody administration, with 4 claims allowed.

Tumor-Targeted Bispecific CD28 Antigen Binding Molecules Patent Grant

USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. covering tumor-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions containing these antibodies, and methods of using the same for cancer treatment.

Novo Nordisk Patent for IL-6 Antagonist Treatment of Diuretic Resistant Heart Failure

The USPTO granted Patent US12600773B2 to Novo Nordisk A/S on April 14, 2026, covering methods of treating diuretic resistant heart failure patients carrying at least one copy of the TMPRSS6 rs855791 allele by administering an IL-6 antagonist. The patent also covers treatment of patients with elevated urine or plasma IL-6 levels requiring diuresis. The patent (CPC: C07K 16/248) names five inventors and issues from Application No. 17519082 filed November 4, 2021, with 10 claims granted.

Methods, Systems, and Devices for Surgical Access and Insertion

The USPTO granted Patent US12599403B2 to the Board of Regents of the University of Nebraska covering methods, systems, and devices for surgical access and insertion into insufflated patient cavities. The patent names Thomas Frederick, Shane Farritor, Jack Mondry, Eric Markvicka, Dmitry Oleynikov, and Jacob Greenburg as inventors and contains 20 claims.

Intraosseous Device Including Sensing Obturator

The USPTO granted Patent US12599405B2 to Bard Access Systems, Inc. covering an intraosseous access system with a driver, needle, and sensor-equipped obturator. The system detects modality changes via an electrical impedance sensor including a passive RFID chip. The patent contains 10 claims and covers the device's control logic that modifies driver operation upon detecting changes.

AngioSafe Catheter - Device and Method for Centering and Crossing Vascular Occlusion

USPTO granted patent US12599398B2 to AngioSafe, Inc. for a catheter device designed to center and cross vascular occlusions. The invention includes a catheter body with central passage, rotatable drive shaft with cutting tip, and spiral springs for maintaining catheter centering through chronic total occlusions. The patent contains 19 claims.

Ultrasonic Treatment Instrument

USPTO granted patent US12599396B2 to Olympus Medical Systems Corp. for an ultrasonic treatment instrument. The patent includes 17 claims and covers a vibration transmitter with first and second supports and a tubular portion. Filing date was August 11, 2023.

Spinal Simplicity Surgical Kit Granted US12599400B1

USPTO granted patent US12599400B1 to Spinal Simplicity, LLC for a surgical kit used in spinal decompression procedures to treat spinal stenosis. The patent covers access instruments, bone reamers, and soft tissue removal instruments for both minimally invasive and open procedures targeting the interlaminar region of the lumbar spine.

Boston Scientific Patent Granted: Tissue Puncturing Medical Device

The USPTO granted US Patent 12599406B2 to Boston Scientific Medical Device Limited on April 14, 2026. The patent covers a medical device for puncturing tissue featuring an elongate member with distal curved and straight portions, an active tip for energy delivery, and a constant diameter layer. The patent contains 13 claims.

Iowa HHS Announces Additional Funding to Fight Opioid Crisis

Iowa HHS announced additional opioid settlement funding availability through House File 1038 (2025), directing 75% of Iowa's opioid settlement money toward crisis response. $10 million is available per funding round with individual grants up to $1 million per project. Eligible activities include prevention, treatment, recovery services, and overdose reversal drug distribution.

CDC Agency Forms Undergoing Paperwork Reduction Act Review

CDC has submitted the information collection request "Poison Center Collaborations for Public Health Emergencies (PCCPHE)" to OMB for review under the Paperwork Reduction Act. The notice allows an additional 30 days for public comments following three comments received from the prior January 2026 notice. America's Poison Centers, a national network of 53 poison centers, serves as CDC's key partner for this surveillance initiative.

Environmental Public Health Training, April 15, 2026

The Indiana Department of Health announced a virtual Environmental Public Health Training scheduled for Wednesday, April 15, 2026 from 9:30am to 11:30am EDT. The event is hosted by IDOH's Local Health Department Program and is open for registration. This is one of ten scheduled training dates in the series.

Low-Viscosity Hardener Manufacturing Method Patent

USPTO granted patent US12600706B2 to Nan Ya Plastics Corporation for a method of manufacturing low-viscosity hardener using isomerization of 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride. The patent covers a hardener crude product with a weight ratio of 3:7 to 7:3 between the two anhydrides, producing a final viscosity of 30-50 cps. The patent includes 8 claims and names Te-Chao Liao, Jung-Jen Chuang, Chung-Yu Chen, and Jung-Tsu Wu as inventors.

Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment

The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.

Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof

USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.

Cannabinoid Derivatives, Precursors and Uses - Patent US12600707B2

USPTO granted patent US12600707B2 to Kare Chemical Technologies Inc. on April 14, 2026, covering new cannabinoid derivatives, precursors, and processes for their preparation. The patent also claims pharmaceutical and analytical uses of these compounds. The patent (10 claims) protects the invention until 2040 based on the September 2020 filing date.

Hutchmed Crystalline Forms Patent Grant US12600713B2

USPTO granted patent US12600713B2 to Hutchmed Limited on April 14, 2026 for crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, a pharmaceutical compound. Inventors are Zhenping Wu, Wenji Li, and Yuping Chu. The patent contains 28 claims and was filed on February 27, 2024.

Gannex Pharma FXR Modulating Compound Patent US12600716B2

USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.

MDMA Prodrug Carbamate Compounds - Apoapsis Holdings

USPTO granted Patent US12600708B2 to Apoapsis Holdings, LLC for novel MDMA prodrug carbamate compounds and synthesis methods. The patent covers 19 claims for compounds that are enzymatically cleaved in vivo to produce low-toxicity alcohols. The inventors include Denton W. Hoyer, Robert F. Roscow, Rong Ling, and Chuanjun Gao.

University of Pittsburgh Heat Shock Protein Modulator Patent for Huntington Disease

USPTO granted patent US12600705B2 to University of Pittsburgh for thiadiazine compounds as heat shock protein modulators. The patent covers therapeutic applications for Huntington disease, other neurodegenerative disorders, and cancer. The patent includes 13 claims.

US12600703B2 - Farnesyl Dibenzodiazepinone Synthesis Patent

USPTO granted patent US12600703B2 to AMO Pharma Ltd. covering methods of synthesizing farnesyl dibenzodiazepinone compounds, including AMO-01. The patent has 4 claims and was filed on May 28, 2021. Patent grants establish legally enforceable intellectual property rights for the disclosed chemical synthesis methods.

Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2

USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.

IBM Granted Patent for Antigen-Binding Proteins Targeting SARS-CoV-2 Variants

USPTO granted IBM (International Business Machines Corporation) Patent US12600764B2 for antigen-binding proteins capable of binding to SARS-CoV-2 coronavirus variants. The patent covers compositions comprising heavy polypeptide chain variable regions with specific amino acid substitutions (R50, I54, L55 positions) that enhance binding to CoV variants. The patent includes 14 claims and was filed on August 27, 2021.

Anti-TDP-43 Binding Molecules and Uses Thereof

The USPTO granted Patent No. US12600766B2 to AC Immune SA covering anti-TDP-43 specific binding molecules, including antibodies and antigen-binding fragments, for diagnosing, preventing, and treating diseases associated with TDP-43 aggregates. The patent lists 15 claims and names Tamara Seredenina, Tamar Magdalena Ziehm, and Tariq Afroz as inventors. The filing date was May 22, 2020, under Application No. 17613444.

ENZENE BIOSCIENCES - GLP-1 Receptor Agonist Preparation Process Patent

The USPTO granted patent US12600759B2 to Enzene Biosciences Limited covering processes for preparing glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs. The patent specifically encompasses processes for preparing liraglutide, D-liraglutide, semaglutide, and D-semaglutide in substantially pure form. The application (17440127), filed on March 19, 2020, contains 4 claims and covers both solid and solution phase preparation methods.

Bioniz Therapeutics - Peptide Cytokine Inhibitors Patent Grant US12600757B2

The USPTO granted Patent US12600757B2 to Bioniz Therapeutics, Inc. on April 14, 2026. The patent covers stable peptide antagonists targeting the gamma-c (γc) subunit binding site to inhibit activity of γc-cytokine family members. The 16 claims apply to therapeutic and cosmetic agents as well as research tools for treating diseases associated with γc-family cytokines.

ASKGENE Pharma Granted Patent for Masked Cytokines

USPTO granted Patent No. US12600762B2 to ASKGENE PHARMA, INC. on April 14, 2026. The patent covers masked cytokines (prodrugs) and methods of use for stimulating the immune system, treating cancer, autoimmune diseases, or infectious diseases. The patent contains 19 claims and was filed on January 11, 2021 under Application No. 17787741.

Knix Wear Moisture Lock Fluid Retention Garment Patent US12599181B2

USPTO granted Patent US12599181B2 to Knix Wear Inc. on April 14, 2026, covering moisture lock fluid retention assemblies for garments. The patent includes 24 claims protecting technology that uses an absorbent layer and moisture-impermeable layer to retain fluids within the garment assembly. The original application (No. 18419152) was filed on January 22, 2024.

3D-Printed Patient-Specific Surgical Guides Patent Granted to RESTOR3D

USPTO granted patent US12599390B1 to RESTOR3D, Inc. covering 3D-printed patient-specific surgical guides and methods for their production and use. The patent includes 14 claims and covers guides with conformal bone engaging surfaces contoured to patient anatomy, designed to avoid soft tissues during surgical procedures.

Endoscope Low Light SPSD Image Sensor Patent

USPTO granted patent US12599294B2 to Schölly Fiberoptic GmbH for an image-recording device combining a single photon sensitive detector (SPSD) with a photodiode-based image sensor in an endoscope for improved low-light imaging. The dual-detection approach captures additional spectral information from a common object area to enhance image quality. The patent contains 24 claims and was filed on July 12, 2022.

Surgical Forceps and Fixation Thereof

USPTO granted patent US12599395B2 to Gyrus ACMI, Inc. on April 14, 2026, covering a surgical forceps design with an outer shaft, first and second jaws with multiple flanges, and an inner shaft. The invention enables jaw movement between open and closed positions through engagement between the inner shaft and jaw flanges. The patent contains 17 claims and was filed on September 12, 2024 under application number 19108304.

Native Chemical Ligation Flow Synthesis - University of Sydney

The USPTO granted Patent US12600746B2 to the University of Sydney covering synthetic methods using native chemical ligation in flow for synthesizing polypeptides. The patent, invented by Richard J. Payne and Tim Chisholm, includes 27 claims and covers selective desulfurization or deselenization of amide-containing compounds with thiol, disulfide, selenol, or diselenide functional groups. The patent application was filed on May 22, 2019, under application number 17057069.

RSV Vaccine Methods for Inactivating and Stabilizing Pre-F Protein

USPTO granted patent US12600750B2 to Xiamen University covering methods for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein. The patent also covers inactivated RSV virus obtained by the method, vaccines comprising the inactivated virus, and uses of the vaccine for preventing or treating RSV infection. The patent names six inventors including Zizheng Zheng, Wei Zhang, and Ningshao Xia, with 19 claims total.

Bioactive Polypeptides for Plant Protection, Growth and Productivity

USPTO granted Patent US12599649B2 to Spogen Biotech Inc. covering bioactive priming polypeptides for agricultural applications. The patent protects formulations containing 7 claims that enhance plant growth, yield, health, longevity, productivity, and vigor, while reducing abiotic stress and providing protection from disease, insects, and nematodes. The patent was filed on July 20, 2018.

Cobra 1/NELF-B as Booster for CD8+ T Cell-Based Therapy - US12600755B2

The USPTO granted Patent US12600755B2 to The George Washington University on April 14, 2026. The patent covers methods of generating T cells with integrated transgenes encoding negative elongation factor (NELF) complex subunits, specifically Cobra 1/NELF-B, for use in treating cancer and infectious disease. The patent contains 19 claims.

Affinity Chromatography of Immunoglobulins Using Pre-capture Flocculation

USPTO granted patent US12600748B2 to RICHTER GEDEON NYRT on April 14, 2026. The patent covers methods for purifying immunoglobulins from cell culture harvest using pre-capture cleaning steps including flocculation and filtration before affinity chromatography. The invention improves eluted immunoglobulin quality, reduces precipitation during chromatography, and extends the lifetime of affinity resin used in large-scale immunoglobulin production.

Compstatin Analogues Patent for Complement Inhibitors

USPTO granted patent US12600749B2 to ZP SPV 3 K/S on April 14, 2026, covering compstatin analogues with improved complement-inhibiting activity. The patent includes 19 claims for peptide variants with modifications at positions 3 and 9, as well as terminal sequences, providing improved binding affinity and solubility. Inventors include Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, and Jens Kvist Madsen.

Modified S2 Subunit Coronavirus Spike Protein Patent US12600751B2

The USPTO granted patent US12600751B2 to inventors Annika Kraemer-Kuehl and Thomas Min Stephan for a modified S2 subunit of coronavirus spike protein featuring a mutation at amino acid position 865. The patent covers a recombinant avian coronavirus spike protein or fragment thereof, along with an immunogenic composition containing the modified spike protein. The patent includes 22 claims with filing date May 6, 2020.

Pharmaceutical Compositions with NSAID and Fatty Acid Oxidase Inhibitor for Treating Infections, Inflammation, Aging

The USPTO granted patent US12599614B2 to MD VAULT LLC for pharmaceutical compositions combining non-steroidal anti-inflammatory drugs (NSAIDs) with fatty acid oxidation inhibitors for treating microbial infectious diseases, associated inflammatory disorders, and aging-related conditions. The patent, filed December 13, 2021, contains 9 claims and covers compositions including agents such as diclofenac (A61K 31/616), mefenamic acid (A61K 31/495), and phenylbutazone (A61K 31/192).

N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for Cancer Treatment

USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation covering substituted N-benzhydrylacetamide inhibitors of Jumanji domain histone demethylases for treating cancer via Wnt signaling pathway inhibition. The patent includes 10 claims and covers compounds according to Formula I and II, along with methods of administering these compounds to subjects needing cancer treatment.

2-AG Enhancing Compositions for Migraine Relief

The USPTO granted Patent US12599600B2 to Arizona Board of Regents on Behalf of the University of Arizona for compositions and methods enhancing 2-arachydonyl glycerol (2AG) activity to prevent and treat headaches, particularly migraines. The patent covers methods for reducing prostaglandin activity and includes claims for pharmaceutical compositions containing 2AG-enhancing compounds.

PDE1 Inhibitors Treat Colon Cancer, USPTO Grant

The USPTO granted Patent US12599603B2 to Intra-Cellular Therapies, Inc. covering phosphodiesterase 1 (PDE1) inhibitors for the treatment of colon cancer and certain tumors. The patent, with inventors Peng Li and Robert Davis, claims 12 method-of-treatment claims. The application was filed on September 3, 2020.

Timolol Compositions for Glaucoma Treatment, Novaliq

USPTO granted patent US12599607B2 to Novaliq GmbH on April 14, 2026, covering pharmaceutical compositions comprising timolol (a β1-receptor blocker) combined with a semifluorinated alkane liquid vehicle for topical ophthalmic administration. The patented compositions are intended for treatment of glaucoma, elevated intraocular pressure, ocular hypertension, and associated symptoms. The patent contains 21 allowed claims.

Methods for Treating Cardiac Valve Disease Using Pharmaceutical Compounds

The USPTO granted Patent US12599608B2 to The Regents of the University of California covering methods of treating cardiac valve disease, including calcific aortic valve disease (CAVD), by administering pharmaceutical compounds of Formulae I-X. The patent names Christina Theodoris and Deepak Srivastava as inventors and includes 4 claims covering therapeutic applications and compound identification methods.

MEDICON Anti-inflammatory, Anti-cancer, and Anti-angiogenic Compounds Patent

The USPTO granted patent US12599599B2 to MEDICON PHARMACEUTICALS, INC. covering compounds of general Formula A-D-Y with anti-inflammatory, anti-cancer, and anti-angiogenic activity for treating inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. The patent includes pharmaceutical compositions, methods of making, and methods of use with 4 claims.

Vemurafenib Salts for Enteroviral Infection Treatment (US12599591B2)

USPTO granted Patent US12599591B2 to Jyväskylän yliopisto for N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (vemurafenib) and pharmaceutical salts for treating enteroviral diseases. The patent contains 14 claims and is classified under CPC codes A61K 31/437 and A61P 31/16.